ENG/中
老虎证券
市场
行情
24/7新闻
产品
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
医药生物股
704.525
-4.529
-0.64%
涨家数:
8
跌家数:
15
平家数:
21
市盈率:
- -
高:
711.737
开:
707.015
低:
697.365
收:
709.054
成交量:
1.83亿
成交额:
1.07亿
市值:
1,047.98亿
流通市值:
1,016.48亿
数据加载中...
总览
新闻资讯
Immutep公布Eftisarc-Neo二期试验在软组织肉瘤中无病生存期积极数据
美股速递
·
2小时前
Racura Oncology旗下Rc220治疗复发或难治性急性髓系白血病无缝IIB/III期Emili试验获首家研究中心批准
美股速递
·
昨天
澳大利亚Nuix股价飙升56%,因Haveli在提出6.37亿美元收购要约后获准查阅财务资料
路透中文
·
昨天
每日特惠-并购
路透中文
·
11/17
Mayne Pharma:Brett Wells 要求公司撤回周五年度股东大会上关于其选举的决议
美股速递
·
11/17
Neuren Pharmaceuticals首销后获1500万美元,销售里程碑金额最高达1.1亿美元并享分层特许权使用费
美股速递
·
11/17
Neuren Pharmaceuticals:Acadia与杏林制药达成Daybue Stix日本独家分销协议
美股速递
·
11/17
Imp761在ACR Convergence 2026发布突破性摘要:T细胞驱动免疫应答抑制呈现统计学显著性与暴露依赖性
美股速递
·
11/09
Mayne Pharma Group拟以5550万澳元出售国际业务
投资观察
·
11/06
Mayne Pharma Group:过渡服务与品牌授权协议将在交易完成后继续有限时间
美股速递
·
11/06
Cynata Therapeutics 获确定性认购承诺,拟通过配售再筹 55 万澳元
投资观察
·
11/04
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK7508/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"医药生物股","latestPrice":704.52496,"timestamp":1795056238844,"preClose":709.0539,"halted":0,"volume":183494861,"delay":0,"changeRate":-0.006387,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-4.528931,"latestTime":"11-19 13:44:03 AEDT","open":707.01495,"high":711.73676,"low":697.365,"amount":106705369,"amplitude":0.020269,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1795064400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1795042800000,1795064400000]],"turnoverRate":0.007275,"increases":9,"decrements":15,"flats":20,"marketCap":104797668009.3125,"floatMarketCap":101648406989.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":711.73676,"amplitude":0.020269,"preClose":709.0539,"low":697.365,"latestPrice":704.52496,"volume":183494861,"delay":0,"open":707.01495,"prevYearClose":644.3692,"prevWeekClose":726.323,"prevMonthClose":726.324,"prevQuarterClose":689.549,"fiveDayClose":735.6,"twentyDayClose":715.245,"sixtyDayClose":670.737,"secType":"PLATE","market":"AU","turnoverRate":0.007275,"marketCap":104797668009.3125,"floatMarketCap":101648406989.875,"timestamp":1795056238844,"nameCN":"医药生物股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":8,"down":15,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199190655","title":"Immutep公布Eftisarc-Neo二期试验在软组织肉瘤中无病生存期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1199190655","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199190655?lang=zh_cn&edition=fundamental","pubTime":"2026-11-19 08:15","pubTimestamp":1795047332,"startTime":"0","endTime":"0","summary":"Immutep公布Eftisarc-Neo二期试验在软组织肉瘤中无病生存期积极数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163696536","title":"Racura Oncology旗下Rc220治疗复发或难治性急性髓系白血病无缝IIB/III期Emili试验获首家研究中心批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163696536","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163696536?lang=zh_cn&edition=fundamental","pubTime":"2026-11-18 20:38","pubTimestamp":1795005488,"startTime":"0","endTime":"0","summary":"Racura Oncology旗下Rc220治疗复发或难治性急性髓系白血病无缝IIB/III期Emili试验获首家研究中心批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684376099","title":"澳大利亚Nuix股价飙升56%,因Haveli在提出6.37亿美元收购要约后获准查阅财务资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2684376099","media":"路透中文","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2684376099?lang=zh_cn&edition=fundamental","pubTime":"2026-11-18 08:12","pubTimestamp":1794960735,"startTime":"0","endTime":"0","summary":"更新 2-澳大利亚Nuix股价飙升56%,因Haveli在提出6.37亿美元收购要约后获准查阅财务资料股价有望创下单日最大涨幅拟议交易报价较该股上一交易日收盘价溢价73%Nuix表示自7月以来已收到Haveli的收购要约全文更新,并在第2段中补充了股价走势路透社11月18日-周三,澳大利亚Nuix公司股价飙升逾50%。Nuix表示,如果Haveli提出每股不低于2.75澳元的具有约束力的要约,其董事会将一致建议股东投票支持该交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261118:nL3S46Z00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXL.AU","BX","BK7132","PRVT","MYX.AU","OML.AU","IE00BLSP4239.USD","BK7045","BK7096","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","AAUM","IE00BGHQF748.EUR","IE0004445239.USD","BK4135","GPZ","BK7508","IE00BN8TJ469.HKD","BK4585","PSP","IE00BBT3K403.USD","BK7016","IEL.AU","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684409604","title":"每日特惠-并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2684409604","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2684409604?lang=zh_cn&edition=fundamental","pubTime":"2026-11-17 19:13","pubTimestamp":1794914005,"startTime":"0","endTime":"0","summary":"每日特惠-并购路透社11月17日-截至周二格林尼治标准时间10:30,已报道以下收购要约、合并、收购和资产处置:** 芬兰卫星运营商Iceye对意大利火箭制造商Avio提出了一项出人意料的全现金收购要约,旨在打造一家欧洲综合航天与国防集团。nL6N46Y0FN** 私募股权公司CVCCVC.AS表示,计划退出一笔价值近30亿欧元的交易,该交易旨在从竞争对手Advent International手中收购意大利原料集团IRCA。nL6N46X1EB** Mayne PharmaMYX.AX表示,匈牙利制药商 Gedeon RichterGDRB.BU已同意以约6.04亿澳元的股权价值收购这家澳大利亚公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261117:nL3S46Y0YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640476718.USD","LU1201861165.SGD","MDLZ","LU0077335932.USD","SG9999017495.SGD","BK4212","LU0130103400.USD","SG9999014880.SGD","LU0130518102.USD","LU0251131958.USD","LU0949170772.SGD","SG9999014906.USD","LU1366333091.USD","LU0011850046.USD","LU0648000940.SGD","SG9999018857.SGD","LU0742534661.SGD","LU0157215616.USD","BK4532","AON","KBWP","LU0048573561.USD","BK7096","BK7508","MYX.AU","SGXZ31699556.SGD","BK4173","LU1804176565.USD","LU0545039389.USD","LU0738911758.USD","IE000M9KFDE8.USD","BK4559","LU1691799644.USD","FTXG","SG9999014914.USD","LU2236285917.USD","LU2265009873.SGD","LU0477156797.USD","PRN.UK","BK4505","LU1983260115.SGD","LU1280957306.USD","BK4585","LU0661504455.SGD","SG9999014898.SGD","LU0251142724.SGD","LU0553294199.USD","BK4588","LU1003077747.HKD","SG9999018865.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115099251","title":"Mayne Pharma:Brett Wells 要求公司撤回周五年度股东大会上关于其选举的决议","url":"https://stock-news.laohu8.com/highlight/detail?id=1115099251","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115099251?lang=zh_cn&edition=fundamental","pubTime":"2026-11-17 13:35","pubTimestamp":1794893708,"startTime":"0","endTime":"0","summary":"Mayne Pharma 表示,Brett Wells 已请求公司撤回原定于周五举行的年度股东大会上有关 Wells 当选的决议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151051926","title":"Neuren Pharmaceuticals首销后获1500万美元,销售里程碑金额最高达1.1亿美元并享分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1151051926","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151051926?lang=zh_cn&edition=fundamental","pubTime":"2026-11-17 06:54","pubTimestamp":1794869648,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals首销后获1500万美元,销售里程碑金额最高达1.1亿美元并享分层特许权使用费","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065171311.SGD","NEU.AU","BK7096","BK7508","ACAD","LU2065169927.USD","BK4139","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125488381","title":"Neuren Pharmaceuticals:Acadia与杏林制药达成Daybue Stix日本独家分销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1125488381","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125488381?lang=zh_cn&edition=fundamental","pubTime":"2026-11-17 06:53","pubTimestamp":1794869626,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals——Acadia就Daybue Stix与杏林制药签订日本市场独家分销协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108523194","title":"Imp761在ACR Convergence 2026发布突破性摘要:T细胞驱动免疫应答抑制呈现统计学显著性与暴露依赖性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108523194","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108523194?lang=zh_cn&edition=fundamental","pubTime":"2026-11-09 06:35","pubTimestamp":1794177307,"startTime":"0","endTime":"0","summary":"Imp761在ACR Convergence 2026发布突破性摘要:T细胞驱动免疫应答抑制呈现统计学显著性与暴露依赖性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165431151","title":"Mayne Pharma Group拟以5550万澳元出售国际业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1165431151","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165431151?lang=zh_cn&edition=fundamental","pubTime":"2026-11-06 09:45","pubTimestamp":1793929525,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd宣布,将以5550万澳元剥离其国际业务部门。\n该交易预计于2027财年第三季度完成,尚需获得澳大利亚竞争与消费者委员会(ACCC)的批准,但无需外国投资审查委员会(FIRB)放行。\n公司已与Evaris Pharma签订具有约束力的协议,出售Mayne Pharma International Pty。交易以股权出售方式构建,Evaris Pharma将据此收购MPI业务。\n交割完成后,过渡性服务及品牌授权协议将在有限时间内继续有效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119088449","title":"Mayne Pharma Group:过渡服务与品牌授权协议将在交易完成后继续有限时间","url":"https://stock-news.laohu8.com/highlight/detail?id=1119088449","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119088449?lang=zh_cn&edition=fundamental","pubTime":"2026-11-06 05:55","pubTimestamp":1793915710,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group:过渡服务与品牌授权协议将在交易完成后继续有限时间","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108528028","title":"Cynata Therapeutics 获确定性认购承诺,拟通过配售再筹 55 万澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108528028","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108528028?lang=zh_cn&edition=fundamental","pubTime":"2026-11-04 09:48","pubTimestamp":1793756926,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics Ltd 宣布,已收到确定性认购承诺,将通过配售方式进一步募集 55 万澳元。更多公司动态请关注 CYP.AX。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}